Teva Pharmaceutical (TEV) Price & Analysis

Compare

36 Followers

TEV Stock Chart & Stats

€29.00

€0.30(1.45%)

At close: Jan 08 4:00 PM EST

€29.00

€0.30(1.45%)

Day’s Range― - ―

52-Week Range€11.15 - €31.10

Previous CloseN/A

Volume3.72K

Average Volume (3M)2.65K

Market Cap

€34.25B

Enterprise Value€52.84B

Total Cash (Recent Filing)€3.56B

Total Debt (Recent Filing)€17.38B

Price to Earnings (P/E)27.4

Beta0.70

Next Earnings

May 13, 2026

EPS Estimate

0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.81

Shares Outstanding1,164,638,700

10 Day Avg. Volume1,827

30 Day Avg. Volume2,651

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)4.53

Price to Sales (P/S)2.08

P/FCF Ratio31.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€33.99

Price Target Upside17.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Profile And DosingDuvakitug's maintenance data showing sustained response with a monthly dosing schedule supports a competitive clinical profile that could improve patient convenience and adoption versus other TL1A therapies.

Commercial Outlook And ValuationAn analyst-led valuation increase after positive clinical data signals higher expected peak sales for duvakitug, implying stronger upside if clinical differentiation translates into market uptake.

R&D Funding And Balance SheetA Royalty Pharma partnership to fund the IL15 program provides non-dilutive capital that can accelerate development while limiting pressure on profitability and supporting balance sheet strength.

Bears Say

Development Timeline UncertaintyThe vitiligo program faces a long development timeline, creating uncertainty around when or if meaningful commercial benefits will be realized.

Market Entry And Competition RiskPivotal trials for duvakitug remain in progress and being behind a first mover could allow a competitor to establish market leadership, constraining Teva's commercial share.

Relative Valuation ConcernThe stock appears expensive versus specialty pharma peers, which could limit upside unless investor perceptions about growth prospects or risk profile change.

Teva Pharmaceutical News

Corcept ‘disappointed’ in court ruling over Teva patent dispute

Corcept Therapeutics Incorporated (CORT) announced that the United States Court of Appeals for the Federal Circuit has found...

14h ago

CORT

TEVA

Midday Fly By: Walmart reports Q4 beat, eBay to acquire Depop from Etsy

The major averages were lower near noon, giving back some of the gains from Wednesday as investors respond...

18h ago

Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva

Biopharma firm Corcept Therapeutics’ ($CORT) shares took a massive beating on Thursday morning. This came after a U.S....

18h ago

CORT

TEVA

Corcept Therapeutics down 18% after appeals court ruling in Teva fight

Shares of Corcept Therapeutics (CORT) have fallen $7.19, or 18%, to $32.63 in morning trading after the United...

19h ago

CORT

TEVA

Teva price target raised to $38 from $37 at BofA

BofA raised the firm’s price target on Teva (TEVA) to $38 from $37 and keeps a Buy rating...

2d ago

SNY

TEVA

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

Teva (TEVA) and Sanofi (SNY) announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, an...

3d ago

SNY

TEVA

Teva price target raised to $45 from $36 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Teva (TEVA) to $45 from $36 and keeps a Buy...

11d ago

TEVA

Teva price target raised to $38 from $35 at Barclays

Barclays analyst Glen Santangelo raised the firm’s price target on Teva (TEVA) to $38 from $35 and keeps...

21d ago

TEVA

Teva price target raised to $40 from $35 at Scotiabank

Scotiabank raised the firm’s price target on Teva (TEVA) to $40 from $35 and keeps an Outperform rating...

22d ago

TEVA

Teva says targeting FY26 gross margin of 54.5%-55.5%

08:55 EST Teva (TEVA) says targeting FY26 gross margin of 54.5%-55.5% Published first on TheFly – the ultimate...

23d ago

TEVA

Teva targets 2030 revenue mid-single digit CAGR

Targets 2030: Operating profit greater than 30%; Adjusted EBITDA growing; FCF greater than $3.5B; Net leverage less than...

23d ago

TEVA

Options Volatility and Implied Earnings Moves This Week, January 26 – January 30, 2026

This week, several major companies will be reporting earnings. Among them are Apple (AAPL), Tesla (TSLA), Microsoft (MSFT),...

25d ago

The Week That Was, The Week Ahead: Macro and Markets, Jan. 25

U.S. stocks finished the week mixed as gains in technology shares helped offset weakness in financial stocks and...

26d ago

Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical, boosting the price...

2d ago

TEVA

TEV FAQ

What was Teva Pharmaceutical’s price range in the past 12 months?

Teva Pharmaceutical lowest stock price was €11.15 and its highest was €31.10 in the past 12 months.

What is Teva Pharmaceutical’s market cap?

Teva Pharmaceutical’s market cap is €34.25B.

When is Teva Pharmaceutical’s upcoming earnings report date?

Teva Pharmaceutical’s upcoming earnings report date is May 13, 2026 which is in 82 days.

How were Teva Pharmaceutical’s earnings last quarter?

Teva Pharmaceutical released its earnings results on Jan 28, 2026. The company reported €0.811 earnings per share for the quarter, beating the consensus estimate of €0.541 by €0.269.

Is Teva Pharmaceutical overvalued?

According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Teva Pharmaceutical pay dividends?

Teva Pharmaceutical does not currently pay dividends.

What is Teva Pharmaceutical’s EPS estimate?

Teva Pharmaceutical’s EPS estimate is 0.46.

How many shares outstanding does Teva Pharmaceutical have?

Teva Pharmaceutical has 1,164,638,700 shares outstanding.

What happened to Teva Pharmaceutical’s price movement after its last earnings report?

Teva Pharmaceutical reported an EPS of €0.811 in its last earnings report, beating expectations of €0.541. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Teva Pharmaceutical?

Currently, no hedge funds are holding shares in DE:TEV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Teva Pharmaceutical Stock Smart Score

Neutral

Fundamentals

Return on Equity

21.37%

Trailing 12-Months

Asset Growth

3.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva Pharmaceutical (TEV) Earnings & Revenues

Historic Earnings Reports

TEV Company Deck

TEV Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented strong progress on the company’s Pivot to Growth: double-digit growth in key innovative brands, improved gross margins, meaningful pipeline validation and clear deleveraging progress. These positives were tempered by dependency on a $500M milestone for headline Q4 growth, a flat generics business with regional softness, near-term one-time inventory/gross-to-net effects that complicate comparability, higher OpEx pressure and persistent clinical/catalyst risk. On balance the strong commercial momentum, improving margin profile and validated pipeline catalysts outweigh the transitory one-time effects and execution risks.View all DE:TEV earnings summaries

TEV Revenue Breakdown

54.45% North America

32.42% Europe

13.12% International Markets

TEV Stock 12 Month Forecast

Average Price Target

€33.99

▲(17.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","25":"€25","38":"€38","18.5":"€18.5","31.5":"€31.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.99619865,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.9854887925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€33.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.08567886,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,18.5,25,31.5,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,30.615092203846153,31.230184407692306,31.84527661153846,32.46036881538461,33.075461019230765,33.69055322307692,34.30564542692308,34.92073763076923,35.535829834615384,36.15092203846154,36.76601424230769,37.381106446153844,{"y":37.99619865,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,30.30657606096154,30.613152121923076,30.919728182884615,31.226304243846155,31.53288030480769,31.83945636576923,32.14603242673077,32.45260848769231,32.75918454865385,33.06576060961538,33.37233667057692,33.67891273153846,{"y":33.9854887925,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30,30.160436835384616,30.32087367076923,30.481310506153847,30.641747341538462,30.802184176923078,30.962621012307693,31.12305784769231,31.283494683076924,31.44393151846154,31.604368353846155,31.76480518923077,31.925242024615386,{"y":32.08567886,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >